Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  leuprolide acetate
Find trials that include:  Any drugs shown
Results 1-22 of 22 for your search:
Start Over
Surgery with or without Docetaxel and Leuprolide Acetate or Goserelin Acetate in Treating Patients with High-Risk Localized Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CALGB 90203, NCI-2009-00496, CDR0000526353, NCT00430183
Radiation Therapy with or without Androgen-Deprivation Therapy in Treating Patients with Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0815, NCI-2011-01948, CDR0000648194, NCT00936390
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
Androgen Deprivation Therapy and Orteronel or Bicalutamide in Treating Patients with Newly Diagnosed Metastatic Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: S1216, NCI-2012-02876, SWOG-S1216, NCT01809691
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-13, NCI-2015-00824, NCT02319837
Radiation Therapy, Hormone Therapy, and Docetaxel in Treating Patients with High-Risk Prostate Cancer Previously Treated with Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 85
Trial IDs: 12313, NCI-2011-01380, 4P-06-3, CR00001450, HS-08-00201, NCT00669162
Stereotactic Body Radiation Therapy and Hormone Therapy in Treating Patients with Localized Intermediate-Risk Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11157, NCI-2013-01332, CIR00008893, NA_00067963, NA_00067963/CIR00003978, NCT01517451
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CR103305, NCI-2013-01912, ARN-509-002, NCT01790126
High-Dose Brachytherapy in Treating Patients with Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: PROS0065, NCI-2015-00089, 350, NCT02346253
Hormone Therapy and Ipilimumab in Treating Patients with Advanced Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC0253, NCI-2009-01214, NCT00170157
Abiraterone Acetate, Radiation Therapy, and Hormone Therapy in Treating Patients with Unfavorable-Risk Localized Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 20 to 80
Trial IDs: Pro00044071, NCI-2013-01803, NCT01717053
Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0993, NCI-2013-00460, NCT01786265
Androgen Deprivation Therapy with or without Palbociclib Isethionate in Treating Patients with RB-Positive Metastatic Hormone-Sensitive Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2013.117, NCI-2014-01922, HUM00082715, NCT02059213
Enzalutamide and Leuprolide Acetate before, during, and after Radiation Therapy in Treating Patients with High-Risk Localized or Locally Advanced Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 to 90
Trial IDs: SCCC-16813, NCI-2014-02533, 082013-032, 8843, Mod5_STU 082013-032, NCI-2014-02510, NCT02064582
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients with Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 135513, NCI-2015-01058, 14-13335, NCI-2015-00154, NCT02168062
Enzalutamide versus Standard Androgen Deprivation Therapy in Reducing Incidence of Metabolic Syndrome in Patients with Advanced Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 19 and over
Trial IDs: 14-0909, NCI-2014-02219, NCT02278185
Enzalutamide, Radiation Therapy, and Hormone Therapy in Treating Patients with Intermediate- or High-Risk Prostate Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13P.461, NCI-2013-02283, 080-38340-J90801, 2013-027, 2970, CCRRC# 2013-027, NCT02023463
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients with Intermediate- or High-Risk Prostate Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-075, NCI-2015-00742, 1501013723, NCT02472275
Intensity Modulated Radiation Therapy with Stereotactic Radiosurgery Boost and Hormone Therapy in Treating Patients with Prostate Cancer
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: CCRO025, NCI-2014-01486, 421870, NCT02064036
Start Over